BioCryst Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview

BioCryst Pharmaceuticals

02/08/2024 17:59

* BioCryst Pharmaceuticals Inc  BCRX.OQ   BCRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 5 for the period ending June 30 2024
    * The Durham North Carolina-based  company is expected to
report a
19.2% increase in revenue to $98.319 million from $82.49 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.The company's guidance on June 6 2024, for
the period ended June 30, was for revenue of $97.000 million.
    * ​LSEG's mean analyst estimate for BioCryst Pharmaceuticals
Inc
is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.00​, above​ its last closing price
of $7.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.22       -0.21      -0.17     Beat    19.4
 Dec. 31 2024  -0.23       -0.24      -0.28     Missed  -14.8
 Sep. 30 2023  -0.24       -0.23      -0.19     Beat    18.6​
 Jun. 30 2023  -0.23       -0.23      -0.24     Missed  -5.1
 ​​Mar.        -0.30       -0.30      -0.28     Beat    6.3
 31 2023                                                
 Jan. 1 0001   -0.13       -0.17      -0.38     Missed  -124.5
                                                        ​
 Sep. 30 2022  -0.29                  -0.23             20.9
 Jun. 30 2022  -0.36       -0.34      -0.32     Beat    6.8
 This summary was machine generated August 2 at 16:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)